

# Testimonials

“...this approach has a clear potential to improve the lives of patients all over the world.”  
 - Dr. Tim M. Jaeger, Global Head of Diagnostics Information Solutions, Roche

We are very intrigued by the innovation and the potential of the technology GLX has developed (the GLX Signature Test) to detect and monitor chronic diseases, and are currently evaluating a potential early-stage partnership”  
 – Amgen (Medical lead, Nicholas Sroczynski and Medical advisor, Christa Broholm).

“The mission of the Wyss DxA is to get transformative diagnostic tests to market and reduce disease burden for patients with major unmet needs. We aim to compress timelines and measure impact on lives. GLX Analytix was invited to join the Industrial Partnership Program and is already forming meaningful partnerships with our stakeholder network,” Rushdy Ahmad, MD, Head of Harvard / Wyss Diagnostics Accelerator

I am writing this letter to express my enthusiastic support for the launch of the GLX Signature test developed by GLX Analytix at Precision Biomarker Laboratories (PBL) at Cedars Sinai in Los Angeles. As a part of the Cedars community and an advocate for advancing medical diagnostics and treatments, I believe that this innovative test has the potential to revolutionize the field of biomarker analysis and greatly benefit patients and healthcare providers alike. With our CLIA-certified laboratory (fall 2023) at PBL (Cedars Sinai), we are well-positioned to facilitate the launch of the GLX Signature test and extend its benefits not only to the local Cedars community but also to individuals across California. Our aim is to become a hub for servicing clinical trials leveraging this technology from across the country, ensuring widespread access to this ground-breaking diagnostic tool. We are confident that this partnership will greatly contribute to advancing medical research, improving patient care, and shaping the future of personalized medicine.

- Susan Mockus, PhD, MBA, Executive Director, Precision Biomarker Laboratory, Cedars Sinai

“The field of neuroscience is in dire need of innovative tools like GLX Signature test, not only to support diagnostic advancements but also to propel the development of therapeutic solutions. Our team will use the test to evaluate vascular dysfunction in dementia and we believe the platform’s ability to assess blood-brain barrier health represents a significant innovation in our field and addresses a critical unmet need for better diagnostic tools. In the future, we aim to use the GLX Signature test for other neurological conditions such as ALS, psychiatric disorders and more. The strong feasibility of the test, coupled with its unique focus on vascular biomarkers, offers a promising avenue for furthering our understanding of these diseases and developing targeted treatments.” – Jeremy Ford, MD, MBA, MS, Harvard Medical University and Mass General Hospital



# Testimonials

“...this approach has a clear potential to improve the lives of patients all over the world.”

- Dr. Tim M. Jaeger, Global Head of Diagnostics Information Solutions, Roche

“In psychiatry, we need objective biomarkers that stratify diagnostics subgroups and are prognostic in for predicting treatment effects across different treatment modalities. We successfully used the GLX Signature test on a large prospective cohort of patients with first-episode major depressive disorder. We have recommended it to our colleagues and will use it in another cohort of treatment-resistant depression patients. Targeting signals from the blood-brain barrier in a simple blood sample is innovative and we are excited about the prospect of a new clinical tool for differential diagnostics and guiding treatment choices.”

- Kristian Reveles Jensen, MD, Neurobiology Unit, Copenhagen University Hospital.

“Brian's research and validation of the glycocalyx for early detection of disease are game-changing. We are at a pivotal moment in personalized healthcare, and GLX Analytix is poised to vastly improve patients' lives with their innovative platform.”

- Michele Colucci, Founder and Managing Partner of DigitalDx Ventures

“GLX Analytix offers a unique and innovative platform with the potential to not only derisk drugs, but also to provide a critical glimpse of a drug's efficacy early in the clinical process. The promise of a dynamic biomarker that measures neuroinflammation from the blood-brain barrier could be game-changing as the pharmaceutical industry is making a return to solving diseases of the central nervous system.” - Ian Laquian, CEO of Kariya Pharmaceuticals

“We are very intrigued by the GLX Signature test as a tool for monitoring flares and treatment effects in Multiple Sclerosis from a blood sample. The approach of measuring endothelial glycocalyx in blood is unique and innovative and the simplicity of an immunoassay is attractive for ease-of-uptake into the clinic if the results prove clinically useful. We are testing our longitudinal CLIMB study that has been a mainstay in testing new technologies over the years and we are excited to see how the GLX Signature test performs”. -- Tanuja Chitnis, MD, Harvard Medical and Mass General Hospital

“We have used GLX Signature test with great success and have observed potentially very important signals in diagnosis and prognosis of patients with schizophrenia (in submission to Nature Neuroscience). Next, we will run the GLX Signature test on a prospective trial focused on early detection of psychosis and schizophrenia. The GLX signature is innovative and has the potential to be a much-sought-after, powerful new tool for the clinic.

- Bjørn Ebdrup, MD, PhD. Head of the Lundbeck Centre for Neuropsychiatric Schizophrenia Research, Copenhagen University Hospital.

